LG 631

Drug Profile

LG 631

Alternative Names: LG631; LG631-CD34; Stem cell therapy - Case Western Reserve University/Opus Bio

Latest Information Update: 05 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Case Western Reserve University
  • Developer Case Western Reserve University; Opus Bio
  • Class Chemoprotectants; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference; MGMT protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No

Highest Development Phases

  • Suspended Chemotherapy-induced damage

Most Recent Events

  • 20 Dec 2016 Suspended - Phase-I for Chemotherapy induced damage in USA (Parenteral) (NCT01269424)
  • 27 Jul 2015 Phase-I clinical trials in Chemotherapy induced damage in USA (Parenteral)
  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top